Education
About Us
Working with TipRanks
Follow Us
Silence Therapeutics (SLN)
NASDAQ:SLN
SLN Analyst Ratings
Moderate Buy
2 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
SLN Stock 12 Month Forecast
Average Price Target
$75.00
▲(1096.17% Upside)
| Highest Price Target$75.00 | Average Price Target$75.00 | Lowest Price Target$75.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
$75
Buy
1096.17%
Upside
Reiterated
11/10/25
Buy Rating Reaffirmed for Silence Therapeutics Amid Strong RNAi Pipeline and Financial PositionWe assess Silence using a discounted cash flow (DCF)- and sum-of-the-parts (SOTP)-based methodology. We assign probabilities of success of 75% for zerlasiran (SLN360) in high for divesiran (SLN124) in PV. We model a build in revenues tied to Silence's RNAi platform in the early 2030s, leading to a modest present value. We employ a 12% discount rate and a terminal multiple of 6.0x. Our model includes potential capital raises of $100M-$200M annually from 2026E to 2027E (vs prior 2025E to 2027E), which could dilute existing shareholders.
William Blair
―
Buy
―
Reiterated
11/04/25
Morgan Stanley
$25
Buy
298.72%
Upside
Reiterated
08/07/25
Chardan Capital
$35
Buy
458.21%
Upside
Reiterated
05/09/25
Goldman Sachs
$6→$4
Sell
-36.20%
Downside
Reiterated
03/04/25
Jefferies
$31→$30
Buy
378.47%
Upside
Reiterated
02/27/25
Analysts Offer Insights on Healthcare Companies: Keros Therapeutics (NASDAQ: KROS), Kura Oncology (NASDAQ: KURA) and Silence Therapeutics (NASDAQ: SLN)Data (1H26). to 2027. AHA'24 update of zerlasiran's (Lp(a) targeting siRNA) showed good efficacy within competitor range (NVS/IONS<SLN<AMGN/ARWR, limited data from LLY for comparison), however, we believe the confusion around measurement endpoint led to the stock sell-off (note). The lack of a clear registrational trial design and the delay of a competitor catalyst from NVS/IONS (previously viewed as the biggest Lp(a) data in 2025 is now in 1H26) have also contributed to the stock weakness. Today, SLN announced that they will not initiate zerlasiran Ph3 trial w/o a partner, which was widely expected. The decision extends cash runway into 2027 (Co ended FY24 w/ $147.3M cash). 2025 First-in-Class siRNA Targeting TMPRSS6 in PV ($1-2B TAM).
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
$75
Buy
1096.17%
Upside
Reiterated
11/10/25
Buy Rating Reaffirmed for Silence Therapeutics Amid Strong RNAi Pipeline and Financial PositionWe assess Silence using a discounted cash flow (DCF)- and sum-of-the-parts (SOTP)-based methodology. We assign probabilities of success of 75% for zerlasiran (SLN360) in high for divesiran (SLN124) in PV. We model a build in revenues tied to Silence's RNAi platform in the early 2030s, leading to a modest present value. We employ a 12% discount rate and a terminal multiple of 6.0x. Our model includes potential capital raises of $100M-$200M annually from 2026E to 2027E (vs prior 2025E to 2027E), which could dilute existing shareholders.
William Blair
―
Buy
―
Reiterated
11/04/25
Morgan Stanley
$25
Buy
298.72%
Upside
Reiterated
08/07/25
Chardan Capital
$35
Buy
458.21%
Upside
Reiterated
05/09/25
Goldman Sachs
$6→$4
Sell
-36.20%
Downside
Reiterated
03/04/25
Jefferies
$31→$30
Buy
378.47%
Upside
Reiterated
02/27/25
Analysts Offer Insights on Healthcare Companies: Keros Therapeutics (NASDAQ: KROS), Kura Oncology (NASDAQ: KURA) and Silence Therapeutics (NASDAQ: SLN)Data (1H26). to 2027. AHA'24 update of zerlasiran's (Lp(a) targeting siRNA) showed good efficacy within competitor range (NVS/IONS<SLN<AMGN/ARWR, limited data from LLY for comparison), however, we believe the confusion around measurement endpoint led to the stock sell-off (note). The lack of a clear registrational trial design and the delay of a competitor catalyst from NVS/IONS (previously viewed as the biggest Lp(a) data in 2025 is now in 1H26) have also contributed to the stock weakness. Today, SLN announced that they will not initiate zerlasiran Ph3 trial w/o a partner, which was widely expected. The decision extends cash runway into 2027 (Co ended FY24 w/ $147.3M cash). 2025 First-in-Class siRNA Targeting TMPRSS6 in PV ($1-2B TAM).
Best Analysts Covering Silence Therapeutics
1 Month
xxx
Success Rate
12/16 ratings generated profit
Average Return
+9.04%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 75.00% of your transactions generating a profit, with an average return of +9.04% per trade.
3 Months
xxx
Success Rate
10/16 ratings generated profit
Average Return
+12.76%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 62.50% of your transactions generating a profit, with an average return of +12.76% per trade.
1 Year
Success Rate
13/21 ratings generated profit
Average Return
+17.34%
reiterated a buy rating 2 months ago
Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 61.90% of your transactions generating a profit, with an average return of +17.34% per trade.
2 Years
xxx
Success Rate
9/21 ratings generated profit
Average Return
-17.47%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 42.86% of your transactions generating a profit, with an average return of -17.47% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
SLN Analyst Recommendation Trends
Rating
Aug 25
Sep 25
Oct 25
Nov 25
Dec 25
Strong Buy
5
3
4
3
2
Buy
2
1
2
2
2
Hold
6
7
12
11
9
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
13
11
18
16
13
Each month's total comprises the sum of three months' worth of ratings.
SLN Financial Forecast
SLN Stock Forecast FAQ
What is SLN’s average 12-month price target, according to analysts?
Based on analyst ratings, Silence Therapeutics’s 12-month average price target is 75.00.
What is SLN’s upside potential, based on the analysts’ average price target?
Silence Therapeutics has 1096.17% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is SLN a Buy, Sell or Hold?
Silence Therapeutics has a consensus rating of Moderate Buy which is based on 2 buy ratings, 0 hold ratings and 0 sell ratings.
What is Silence Therapeutics’s price target?
The average price target for Silence Therapeutics is 75.00. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $75.00 ,the lowest forecast is $75.00. The average price target represents 1096.17% Increase from the current price of $6.27.
The highest analyst price target is $75.00 ,the lowest forecast is $75.00. The average price target represents 1096.17% Increase from the current price of $6.27.
What do analysts say about Silence Therapeutics?
Silence Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
How can I buy shares of SLN?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.